Y
Yumiko Shiraki
Publications - 9
Citations - 824
Yumiko Shiraki is an academic researcher. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 7, co-authored 9 publications receiving 774 citations.
Papers
More filters
Journal ArticleDOI
Vitamin K2 (Menatetrenone) Effectively Prevents Fractures and Sustains Lumbar Bone Mineral Density in Osteoporosis
TL;DR: It is suggested thatitamin K2 treatment effectively prevents the occurrence of new fractures, although the vitamin K2–treated group failed to increase in LBMD.
Journal ArticleDOI
Association of bone mineral density with apolipoprotein E phenotype.
Masataka Shiraki,Yumiko Shiraki,Choju Aoki,Takayuki Hosoi,Satoshi Inoue,Masao Kaneki,Yasuyoshi Ouchi +6 more
TL;DR: The Apo E4 allele is associated with a low bone mass in postmenopausal Japanese women and is a significant, independent predictor of the Z score of the lumbar BMD.
Journal ArticleDOI
Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment
Masataka Shiraki,Tatsuhiko Kuroda,Yumiko Shiraki,Shiro Tanaka,Tsuyoshi Higuchi,Mitsuru Saito +5 more
TL;DR: Cox’s proportional hazard model demonstrated that age, prevalent fracture, pentosidine, and homocysteine were independent predictors of the incident vertebral fracture rate under bisphosphonate treatment.
Journal ArticleDOI
Serum 25-hydroxyvitamin D below 25 ng/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women
Shiro Tanaka,Tatsuhiko Kuroda,Yasushi Yamazaki,Yumiko Shiraki,Noriko Yoshimura,Masataka Shiraki +5 more
TL;DR: 25(OH)D is a leading risk factor for long bone fracture comparable to BMD in Japanese postmenopausal women and the contribution of 25( OH)D to fracture risks is substantial even below 25 ng/mL and is possibly site-specific.
Journal ArticleDOI
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment
TL;DR: Measurement of undercarboxylated osteocalcin may be useful for assessing fracture risk in patients receiving amino-BP treatment, indicating that older age, a greater number of prevalent fractures and higher ucOC levels, and lower LBMD are risks for incident fractures despite use of amino- BP.